Do you want to read an article? Please log in or register.
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT
Cardiovascular Risk and Diseases
Related content
Heart, Artery and Coronary DiseasesLipid-Lowering DrugsThrombosis and Stroke
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Eur Heart J.
Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators.
doi: 10.1093/eurheartj/ehw377
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA Cardiol.
Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP
doi: 10.1001/jamacardio.2020.3151.
Cardiovascular Risk and Diseases
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, BETonMACE Investigators and Committees.
doi: 10.1001/jama.2020.3308.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Lancet Diabetes Endocrinol.
Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA
doi: 10.1016/S2213-8587
Heart Failure
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Circulation
Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi E, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1161/CIRCULATIONAHA.120.051824
RECOMMENDED
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
doi: 10.1016/S0140-
Cardiovascular Risk and Diseases
Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study
Diabet Med
Özbek BT, Modin D, Møgelvang R, Jørgensen PG, Jensen MT, Schnohr P, Gislason GH, Biering-Sørensen T
doi: 10.1111/dme.14627
Cardiovascular Risk and Diseases
Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study
Diabet Med
Özbek BT, Modin D, Møgelvang R, Jørgensen PG, Jensen MT, Schnohr P, Gislason GH, Biering-Sørensen T
doi: 10.1111/dme.14627
Atrial Fibrillation
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
Eur Heart J.
Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M
doi: 10.1093/eurheartj/ehz732.